BD (Becton, Dickinson and Company) will highlight advanced biologics drug delivery systems at Pharmapack 2026, Europe’s top drug delivery event. The conference takes place January 21–22 in Paris. BD’s participation underscores the company’s dedication to innovative therapies while enhancing patient experiences and self-administration options worldwide.

At Pharmapack, BD will present its portfolio supporting pharmaceutical and biotechnology companies developing biologics, vaccines, GLP-1 therapies, and acute care medicines. In addition, the ZebraSci services help partners reduce risks in combination product development from concept to commercialization.

“Biologics drug delivery requires balancing performance, usability, and reliability as patient expectations grow and therapies become more complex,” said Fernand Goldblat, Vice President at BD Medical–Pharmaceutical Systems. He explained that collaboration with customers enables scalable, patient-focused solutions throughout product lifecycles.

BD’s booth 4G28 will feature live demonstrations of cutting-edge delivery technologies. Visitors can explore solutions addressing high-viscosity formulations, large-volume subcutaneous delivery, and dual-drug therapies. Furthermore, demonstrations emphasize traceable manufacturing and connected processes to meet evolving industry standards.

A central focus of the exhibit is BD’s advanced biologics drug delivery technologies, designed to transition therapies from hospital settings to patient-centric care environments. These solutions streamline treatment delivery, support flexible dosing, and allow for convenient at-home administration.

Among the highlighted devices is the BD Libertas™ Wearable Injector, a ready-to-use system for subcutaneous administration of high-dose biologics. This wearable device enhances patient comfort while enabling smooth transitions from intravenous therapy to self-administration at home.

BD will also present the BD Neopak™ XtraFlow™ Glass Prefillable Syringe, engineered for high-viscosity biologics. Its shorter needle and thinner walls reduce injection force and variability, improving usability for patients and healthcare providers. These innovations demonstrate BD’s commitment to patient-centered biologics drug delivery.

Another featured solution is the BD iDFill™ Individual Prefillable Syringe Identification system. Using RFID technology, it enhances traceability and operational efficiency during filling, finishing, and distribution. As a result, biologic drug delivery workflows become more reliable and efficient.

Beyond these flagship products, BD’s booth will showcase the BD Effivax™ Glass Prefillable Syringe for vaccines and the BD Hylok™ Glass Prefillable Syringe for acute drugs and hyaluronic acid. These offerings highlight BD’s comprehensive biologics-focused portfolio.

As a Premium Partner of Pharmapack 2026, BD will contribute to educational sessions, including keynote addresses and panel discussions. On January 21 at 14:10, the keynote “Are We There Yet? Dynamics in the High-Dose Biologics Market” will explore trends and challenges in biologics drug delivery. Later, at 15:50, a panel discussion titled “Patient-Centric Approaches to Complex Drug Delivery Challenges” will feature industry experts.

The event will also include learning labs that provide deeper technical insights into biologics drug delivery solutions. Sessions will focus on optimizing high-viscosity biologic administration using advanced syringe platforms and evaluating container closure integrity under real-world conditions.

BD’s participation demonstrates its ongoing commitment to developing biologic drug delivery innovations. By offering scalable and flexible technologies, BD helps partners deliver next-generation therapies safely and effectively to patients worldwide.

Additionally, BD’s exhibit and conference sessions emphasize practical solutions for healthcare providers, ensuring high-quality outcomes in biologic drug delivery. The company bridges the gap between complex therapies and patient-friendly administration.

Overall, BD’s presence at Pharmapack 2026 illustrates its leadership in biologics drug delivery innovation. Through collaborative partnerships, advanced technologies, and educational engagement, BD aims to improve treatment delivery and patient outcomes globally.

BD’s participation also showcases how strategic innovation can transform biologic drug delivery. By empowering patients, optimizing workflows, and improving therapy effectiveness, BD continues shaping the future of healthcare.

By highlighting its full portfolio, BD encourages collaboration with pharmaceutical and biotechnology partners to address emerging trends in biologics drug delivery. The company’s initiatives support sustainable and scalable solutions for present and future healthcare challenges.

Ultimately, Pharmapack 2026 provides a platform for BD to demonstrate its commitment to biologics drug delivery excellence. Through innovation, collaboration, and education, BD continues to drive meaningful improvements in therapy delivery and patient care worldwide.